EZN-2208, an inhibitor of HIF-1α, has displayed anti-tumor activity both as monotherapy and in combination with bevacizumab in phase I clinical trials involving refractory solid tumors (140, 141). The gene discussed is HIF1A; the disease is neoplasm.